Cargando…
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial
BACKGROUND: The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of accuracy in identifying HR patients with conventional risk f...
Autores principales: | Filleron, Thomas, Le Guellec, Sophie, Chevreau, Christine, Cabarrou, Bastien, Lesluyes, Tom, Lodin, Sabrina, Massoubre, Angélique, Mounier, Muriel, Poublanc, Muriel, Chibon, Frédéric, Valentin, Thibaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395339/ https://www.ncbi.nlm.nih.gov/pubmed/32736540 http://dx.doi.org/10.1186/s12885-020-07207-3 |
Ejemplares similares
-
CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study
por: Frezza, Anna Maria, et al.
Publicado: (2022) -
The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
por: Lesluyes, Tom, et al.
Publicado: (2017) -
Study protocol of the TEC-ORL clinical trial: a randomized comparative phase II trial investigating the analgesic activity of capsaicin vs Laroxyl in head and neck Cancer survivors presenting with neuropathic pain sequelae
por: Boden, Antoine, et al.
Publicado: (2022) -
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022) -
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)